Overview of a global clinical trial program with turoctocog alfa, a new recombinant factor VIII: the guardian™ program
The influence of co-morbidities on annualized bleeding rates in patients with severe hemophilia A: experiences from the pivotal turoctocog alfa prophylaxis trial (guardianTM1)
Motivational Interviewing and Health Behavior Change: An Educational Intervention for Healthcare Professionals
Characterization of the Binding of a Novel Recombinant Single-Chain FVIII to von Willebrand Factor
Objective: The binding behavior of rVIII-SingleChain to plasma-derived von Willebrand Factor (pdVWF) was assessed in surface plasmon resonance (SPR) studies. Methods: The purification of VWF from human…
Preclinical PK/PD Characteristics of rVIII-SingleChain, a Novel Recombinant Single-Chain FVIII
Objective: A novel recombinant coagulation factor VIII, rVIII-SingleChain, produced without added animal- or human-derived materials, is currently in a clinical phase I/III program (AFFINITY). The present non-clinical studies…
Preclinical Characteristics of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII With Albumin (rVIIa-FP)
Relative importance of treatment characteristics to patients and parents of children with hemophilia
Adherence and outcomes in hemophilia
Objective: Adherence to treatment has an important impact on health outcomes in chronic conditions, but the relationship between adherence to prophylactic infusions and outcomes in hemophilia is not well documented. This study…
Dosing intervals and bleeding rates before and following treatment with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B: Experience from the B-LONG study
Objective: Safety and efficacy of long-lasting recombinant factor IX Fc fusion protein (rFIXFc), currently being developed to provide extended protection from bleeding in hemophilia B patients, were demonstrated in the phase 3 B-…
The National Hemophilia Program Coordinating Center - Assessing Support Needs of HTC Staff